The company remains in a pre-revenue phase, with quarterly R&D expenditures fluctuating between $14.7 million and $23.4 million, driving consistent operating losses that reached $22.3 million in 2026Q1.
| Sales/Revenue | 0 | 0 | 0 | 0 | 654K | 1.66M | 518.48K |
| Revenue Growth % | - | - | - | -100% | -60.53% | 219.59% | - |
| Cost of Goods Sold | 546K | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - |
| Gross Profit | -546K | 0 | 0 | 0 | 654K | 1.66M | 518.48K |
| Gross Margin % | - | - | - | - | 100% | 100% | 100% |
| Gross Profit Growth % | - | - | - | -100% | -60.53% | 219.59% | - |
| Operating Expenses | 97.24M | 109.26M | 105.77M | 68.51M | 61.16M | 52.29M | 5.11M |
| OpEx % of Revenue | - | - | - | - | 9352.14% | 3155.94% | 984.86% |
| Selling, General & Admin | 35.46M | 45.46M | 31.68M | 15.38M | 12M | 7.17M | 787.5K |
| SG&A % of Revenue | - | - | - | - | 1835.02% | 432.89% | 151.89% |
| Research & Development | 62.33M | 63.8M | 74.09M | 53.13M | 49.16M | 45.12M | 4.32M |
| R&D % of Revenue | - | - | - | - | 7517.13% | 2723.05% | 832.97% |
| Other Operating Expenses | -546K | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -97.78M | -109.26M | -105.77M | -68.51M | -60.51M | -50.64M | -4.59M |
| Operating Margin % | - | - | - | - | -9252.14% | -3055.94% | -884.86% |
| Operating Income Growth % | - | -3.3% | -54.37% | -13.23% | -19.5% | -1003.73% | - |
| EBITDA | -95.66M | -107.18M | -103.76M | -66.67M | -59.36M | -50.62M | -4.59M |
| EBITDA Margin % | - | - | - | - | -9077.06% | -3055.16% | -884.86% |
| EBITDA Growth % | 16.27% | -3.29% | -55.64% | -12.31% | -17.26% | -1003.45% | - |
| D&A (Non-Cash Add-back) | 2.12M | 2.08M | 2M | 1.84M | 1.15M | 13K | 0 |
| EBIT | -89.47M | -99.75M | -98.2M | -66.19M | -59.19M | -50.62M | -4.59M |
| Net Interest Income | 6.91M | 5.92M | 7.44M | 2.66M | 1.23M | 15K | -147.15K |
| Interest Income | 7.09M | 6.13M | 7.56M | 2.87M | 1.32M | 15K | 0 |
| Interest Expense | 183K | 206K | 114K | 205K | 91K | 0 | 147.15K |
| Other Income/Expense | 10.28M | 9.3M | 7.43M | 2.12M | 1.23M | 15K | -565K |
| Pretax Income | -87.5M | -99.96M | -98.33M | -66.39M | -59.28M | -50.62M | -5.15M |
| Pretax Margin % | - | - | - | - | -9063.76% | -3055.04% | -993.83% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -87.5M | -99.96M | -98.33M | -66.39M | -59.28M | -50.62M | -5.15M |
| Net Margin % | - | - | - | - | -9063.76% | -3055.04% | -993.83% |
| Net Income Growth % | 19.95% | -1.66% | -48.11% | -12.01% | -17.1% | -882.42% | - |
| Net Income (Continuing) | -87.5M | -99.96M | -98.33M | -66.39M | -59.28M | -50.62M | -5.15M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.08 | -1.86 | -3.09 | -2.49 | -2.40 | -2.01 | -0.20 |
| EPS Growth % | 56.06% | 39.81% | -24.1% | -3.75% | -19.4% | -905% | - |
| EPS (Basic) | - | -1.86 | -3.09 | -2.49 | -2.36 | -2.01 | -0.20 |
| Diluted Shares Outstanding | 81.18M | 53.65M | 31.79M | 26.65M | 25.17M | 25.17M | 25.17M |
| Basic Shares Outstanding | 81.18M | 53.65M | 31.79M | 26.65M | 25.17M | 25.17M | 25.17M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
Imminent liquidity and dilution risk
As indicated by recent financial disclosures, LXEO maintains a high-intensity R&D cost structure, with quarterly expenditures consistently ranging between $14.7 million and $23.4 million, reflecting the significant capital requirements necessary to advance its diversified pipeline of gene therapy candidates through early-stage clinical trials.
The company's cost profile is dominated by R&D, which remains the primary driver of its quarterly operating losses. Investors should monitor the efficiency of these expenditures, as the lack of commercial revenue means that every dollar spent on clinical development directly accelerates the depletion of the company's limited cash reserves.
Based on reported income statements, LXEO consistently utilizes stock-based compensation, averaging approximately $2.8 million per quarter, which serves to preserve cash while attracting specialized scientific talent, though this practice simultaneously dilutes existing shareholders and complicates the assessment of true underlying operational expenses.
While stock-based compensation is a standard tool for clinical-stage biotech firms, the reliance on equity-based incentives suggests a strategic effort to manage cash burn. Analysts should adjust for these non-cash charges when evaluating the company's true cash-burn rate to better understand the timeline until the next potential capital raise.
According to the provided income statement data, LXEO exhibits no meaningful operating leverage, as the company remains in a pre-revenue phase where operating losses have fluctuated between $15.0 million and $33.8 million per quarter, driven primarily by the scaling of clinical trial activities.
The absence of revenue means that operating expenses currently scale in direct proportion to clinical trial enrollment and manufacturing requirements rather than commercial success. This lack of leverage implies that the company's financial performance will remain highly sensitive to trial outcomes and regulatory milestones until a product reaches the market.
As reported in financial filings, the company's cash position of $63 million appears increasingly precarious when measured against the quarterly operating loss of approximately $20 million to $23 million, suggesting that the current operational trajectory may necessitate external financing within the next twelve months.
Short-sellers may focus on the potential for significant shareholder dilution if the company is forced to raise capital in a challenging biotech funding environment. The sustainability of the current pipeline breadth warrants further investigation, as management may eventually be forced to prioritize specific programs to extend the company's operational runway.
Quick answers to the most common questions about buying LXEO stock.
For fiscal year 2025, Lexeo Therapeutics, Inc. Common Stock (LXEO) reported total revenue of $0.0M. This represents a 100.0% decline compared to $0.5M in 2020.
Lexeo Therapeutics, Inc. Common Stock (LXEO) reported a net loss of $100.0M for the fiscal year ending 2025.